|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2005-3-9
|
|
pubmed:abstractText |
To determine whether recombinant human leukemia inhibitory factor (rhuLIF, AM424, emfilermin) can prevent or ameliorate the development of chemotherapy-induced peripheral neuropathy (CIPN) after treatment with carboplatin (AUC 6) and paclitaxel (175 mg/m(2) over 3 hours).
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:ArezzoJosephJ,
pubmed-author:BartleyPeterP,
pubmed-author:ChiaMichaelM,
pubmed-author:DalyMichaelM,
pubmed-author:DavisIan DID,
pubmed-author:GreenMichaelM,
pubmed-author:HarrisonLeonieL,
pubmed-author:KiersLynetteL,
pubmed-author:MacGregorLachlanL,
pubmed-author:QuinnMichaelM,
pubmed-author:RosenthalMarkM,
pubmed-author:XXX
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1890-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15756015-Adult,
pubmed-meshheading:15756015-Aged,
pubmed-meshheading:15756015-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15756015-Carboplatin,
pubmed-meshheading:15756015-Cytokines,
pubmed-meshheading:15756015-Dose-Response Relationship, Drug,
pubmed-meshheading:15756015-Double-Blind Method,
pubmed-meshheading:15756015-Female,
pubmed-meshheading:15756015-Humans,
pubmed-meshheading:15756015-Interleukin-6,
pubmed-meshheading:15756015-Leukemia Inhibitory Factor,
pubmed-meshheading:15756015-Lipase,
pubmed-meshheading:15756015-Male,
pubmed-meshheading:15756015-Middle Aged,
pubmed-meshheading:15756015-Neoplasms,
pubmed-meshheading:15756015-Neural Conduction,
pubmed-meshheading:15756015-Paclitaxel,
pubmed-meshheading:15756015-Peripheral Nervous System Diseases,
pubmed-meshheading:15756015-Placebos,
pubmed-meshheading:15756015-Prospective Studies,
pubmed-meshheading:15756015-Proteins
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy.
|
|
pubmed:affiliation |
Austin Health, Studley Road, Heidelberg, Victoria 3084, Australia. Ian.Davis@ludwig.edu.au
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase II
|
